Radyus Research Appoints Anna Walz to its Board of Directors

April 27, 2023

Atlanta, GA, April 5, 2023 – Radyus Research, a preclinical research organization, has appointed Anna Walz to its Board of Directors to help support the company’s growth and business development among mid-size and large pharma clients. She brings deep experience with her holistic approach that connects the early stages of preclinical pharmaceutical drug development with ultimate patient delivery and medical affairs.

Walz spent over 25 years in medical affairs, global medical consulting, and has a proven track record in entrepreneurial innovation and leadership.

“We are excited to welcome Anna to the Radyus team and look forward to benefiting from her experience building and expanding healthcare businesses.” – Paul Tebbey, Board Member and co-founder of Radyus Research.

Walz was previously the Founder and CEO of medical analytics consultancy MedEvoke, which was successfully acquired by Inizio Health in 2021. We hope Walz’s track record enables Radyus Research to grow our business sustainably in the competitive fee-for-service research market.

As an entrepreneur, Walz harnessed her skills as a visionary to actively seek and reveal niche markets in the pharma and biotech industries, leading her to build a successful global consulting company. Most recently, Walz has been involved with The Medical Voice Network, which she co-founded to establish a community of cross-functional experts from pharma and biotech to disrupt traditional silos in the oncology and drug development space. She aims to develop earlier partnerships to increase efficiency regarding cancer cures for patients in need.

“I really believe in what Radyus is doing, and the direction in which the CEO, Marta New, is leading the company. I hope I can use my experiences and lessons learned to make a small contribution to their growth and create holistic practices we want to see reflected in the industry.” – Anna Walz

Walz is a sought-after subject matter expert and frequent speaker on many topics, including medical strategy, launch excellence, impact metrics for medical affairs, female entrepreneurship, and diversity in the biosciences. In addition to holding a bachelor’s degree in marketing and communications from Seton Hall University, Walz has invested heavily in continuing her education and is a graduate of the Tuck-WBENC Executive Education program and the Entrepreneurial Master’s Program (EMP), a collaboration between the Entrepreneur’s Organization and Massachusetts Institute of Technology. Walz is also a vocal champion of The Medical Affairs Professional Society, serving on their Board of Directors, and is Chair of the Finance Committee for the Ambassadors of Alliance. She is a long-standing Trustee at Hunterdon Healthcare, serving as Chair of the Community Needs Committee and an active Health System’s Strategic Planning Committee member.


Radyus Research is a fully integrated preclinical research organization that offers comprehensive drug development services. Last year was our most successful to date, where we worked on 42 projects for over 20 biotech clients across the globe. Projects ranged from indication selection, target product profiling, product development planning, and experimental design to program management, manufacturing, and regulatory strategy. We also recruited new team members, doubling our core team, in support of client projects in several areas including oncology, immunology, respiratory, and rare diseases.

So far in 2023, Radyus has been working with sixteen different clients on multiple ongoing projects. Some of our clients have been continuously working with us for over three years and counting. We pride ourselves on this long-term partnership approach.